3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasm Metastasis
2
Uveal Melanoma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Differentiated Thyroid Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Melphalan
3
tebentafusp
1
sargramostim
1
fotemustine
1
aflibercept
1
Ranibizumab
1
Nivolumab
1
Neoadjuvant Therapy
1
Melatonin
1
MART-1 Antigen
1
Ipilimumab
1
Eye Enucleation
1
Dacarbazine
1
Colony-Stimulating Factors
1
Chemotherapy, Cancer, Regional Perfusion
1
Brachytherapy
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Uveal Melanoma
×
AZD 6244
×
Clear all
NCT01974752
2017-01-05
SUMIT
AstraZeneca
Phase 3
Completed
152 enrolled
14 charts